Table 1 Basis characteristics

Gender (Number of patients (%))

Scores

 Male

85 (51.5%)

QMG modified (value ± SD)

0.49 ± 0.4

 Female

80 (48.5%)

 Female

0.56 ± 0.4

Age at symptom onset (years ± SD)

54.4 ± 19.3

 Male

0.42 ± 0.3

 Female

50.1 ± 20.8

 Missing data (number of patients)

0

 Male

58.4 ± 17.0

Age at diagnosis (years ± SD)

55.4 ± 18.9

MG-ADL (value ± SD)

3.99 ± 3.5

 Female

51.9 ± 20.2

 Female

4.8 ± 3.7

 Male

58.7 ± 17.1

 Male

3.0 ± 3.0

BMI (kg/m² ± SD)

28.0 ± 5.5

 Missing data (number of patients)

110

 Female

27.0 ± 5.8

 Male

29.1 ± 5.0

MG-QoL15 (value ± SD)

16.7 ± 13.0

 Missing data (number of patients)

41

 Female

19.7 ± 12.4

 Male

13.0 ± 13.0

MGFA (number of patients (%))

 Missing data (number of patients)

101

I

18 (10.9%)

II

70 (42.4%)

Treatment (number of patients (%))

 IIA

34 (20.6%)

Pyridostigmine

164 (99.4%)

 IIB

14 (8.5%)

Pyridostigmine extended release

139 (84.2%)

 Not class.

22(13.3%)

Glucocorticosteroids

143 (86.7%

III

31 (18.8%)

IVIG

44 (26.7%)

 IIIA

17 (10.3%)

AZA

120 (72.7%)

 IIIB

10 (6.1%)

MMF

47 (28.5%)

 Not class.

4 (2.4%)

Thymectomy (number of patients (%))

52 (31.5%)

IV

27 (16.4%)

 IVA

2 (1.2%)

Thymoma

17 (37.8%)

 IVB

24 (14.5%)

Thymic hyperplasia

12 (26.7%)

 Not class.

1 (0.6%)

No pathology

16 (35.6)

V

19 (11.5%)

Myasthenic crisis in the past

Serological status (number of patients (%))

(number of patients (%))

No

123 (74.5%)

Anti-AChR-AB (+) (missing data n = 1)

137 (83.5%)

Yes

42 (25.5%)

Anti-MuSK-AB (+) (missing data n = 75)

5 (5.6%)

 - 1 crisis

29 (17.6%)

Anti-Titin-AB (+) (missing data n = 63)

36 (35.3%)

 - 2 crisis

5 (3.0%)

Anti-LRP4-AB (+) (missing data n = 161)

0 (0%)

 - > 2 crisis

8 (4.8%)